Non-diabetic men treated with semaglutide (Ozempic/Wegovy) appeared to be at an increased risk for developing erectile dysfunction (ED) and hypogonadism; however, the rate was low at 1.4%, according to a retrospective analysis presented at the 24th Annual Fall Scientific Meeting of Sexual Medicine Society of North America in San Diego, California. This is the first study regarding how Ozempic and similar drugs may affect sexual function in non-diabetic men. However, other studies have found that long-term use of dulaglutide, for instance, might reduce the incidence of moderate or severe erectile dysfunction in men with type 2 diabetes. This all means that more studies are needed to understand these findings and further studies are warranted to find out more about the connection between GLP-1 drugs and sexual function.
Always consult with your healthcare provider if you have any concerns about taking these drugs.
Visit www.TexasSexualHealth.com to learn more.
Like
Share
Follow
SUBSCRIBE
Thanks for watching
Netscribes is a global data, insights and digital fulfilment firm